Belgium’s National Institute of Radioelements (IRE) announced on April 30 that it has produced its first batch of commercial molybdenum-99 from low-enriched uranium (LEU) targets. The first batch of Mo-99, whose decay product, technetium-99m, is used in nuclear medicine for diagnostic imaging, was produced for the U.S. health market. IRE said that the conversion to LEU represents a key milestone for the institute in the global commitment to end the civilian use of highly enriched uranium (HEU) for the production of Mo-99.

Advanced reactor cores are being designed for higher efficiencies and longer lifetimes, but to get there, they need high-assay low-enriched uranium (HALEU).

Enriched to between 5 and 19.75 percent fissile U-235, HALEU is packed with nuclear potential. It can be used as a feedstock for the demonstration of new fuel designs, from uranium alloys to ceramic pellets and liquid fuels. Those fuels can enable advanced reactor and microreactor demonstrations. Operating light-water reactors could potentially transition to HALEU uranium oxide fuels for extended operating cycles and improved plant economics.